CODA is located in South San Francisco, CA. The Company is creating the ability to control neurons with its revolutionary chemogenetics-based technology. CODA expects this treatment will produce substantially improved and durable results while potentially avoiding off-target/adverse effects of currently available treatments.ĬODA Biotherapeutics, Inc., is a preclinical-stage biopharmaceutical company developing an innovative gene delivery platform to treat intractable neurological disorders, with an initial focus on epilepsy, movement disorders, and neuropathic pain. The receptor is designed to be quiescent in the transduced cells but will specifically and dose-dependently inhibit neurons when exposed to a novel, orally bioavailable small-molecule activator agonist drug. The Company's innovative treatment aims to modulate specific neuronal circuits via adeno-associated virus (AAV)-mediated delivery of an engineered, inhibitory receptor by standard-of-care neurosurgical procedures. ![]() The Epilepsy Foundation estimates that one-third of people with epilepsy live with uncontrollable seizures because no available treatments are effective.ĬODA Biotherapeutics is developing a paradigm-shifting chemogenetic approach to treating neurological disorders. ![]() Patients suffer from stigmatization, social isolation, combined with disability, educational underachievement, and poor employment outcomes. According to the World Health Organization, recurrent seizures disrupt normal brain functions, lead to neuronal loss, and result in cognitive and emotional deficits. T/Cs, PAYMENT, LOCATION INFO, Try SAM, our Circular Economy Solution, Innovive Racks, Innovive Racks, Thermo Scientific Safety Cabinet. Focal epilepsy represents approximately 60 percent of all epilepsy (National Institute of Neurological Disorders and Strokes). Epilepsy is characterized by unpredictable seizures and the term "focal" epilepsy is used to describe seizures that initiate from a specific location in the brain, typically in one hemisphere. We look forward to advancing our epilepsy program as rapidly as possible so that we can provide new hope for patients suffering with intractable focal epilepsies."Įpilepsy is one of the most common chronic neurological diseases and, according to the Centers for Disease Control, affects more than 65 million people around the world of which 3.4 million are in the U.S. Michael Narachi, president and CEO of CODA, said, "These results are exciting as the quantitative relationship between receptor expression and efficacy helps to identify the target range for receptor dosing in development-related studies. The data will be presented by Susan Catalano, Ph.D., CODA's chief science officer, at the 2022 Epilepsy Foundation Pipeline Conference being held June 5-6, 2022. Data also demonstrated that the expression of CODA's lead receptor is highly correlated with a reduction in seizure frequency. Results showed that the rapid reduction in seizures is consistent with the pharmacokinetics of the activator drug in mouse models. ("CODA"), a preclinical-stage biopharmaceutical company using a chemogenetic platform to treat prevalent intractable neurological disorders, today announced that preclinical data from the Company's focal epilepsy program demonstrated that treatment with the Company's lead engineered receptor and small molecule activator drug significantly reduced focal seizure frequency in vivo. SOUTH SAN FRANCISCO, Calif., J/PRNewswire/ - CODA Biotherapeutics, Inc. As part of the financing, David Stack, chairman and CEO of Pacira Biosciences, will join CODA's board of directors.Data presented at 2022 Epilepsy Foundation Pipeline Conference provide additional in vivo proof of concept for CODA's engineered receptors and activator drugs in controlling seizures The financing round was led by non-opioid pain management company Pacira Biosciences together with CODA's existing investors, MPM Capital and Versant Ventures, and a new venture debt round with Silicon Valley Bank. CODA added that it expects this treatment will produce substantially improved and durable results while potentially avoiding off-target/adverse effects compared to current treatments. ![]() The receptor is designed to be quiescent in the transduced cells but will inhibit neurons when exposed to a novel, orally bioavailable small molecule agonist, the company said. CODA's treatment aims to modulate specific neuronal circuits via adeno-associated virus-mediated delivery of an engineered, inhibitory receptor by standard-of-care neurosurgical procedures. CODA is developing a gene therapy approach by deploying a chemogenetic strategy for treating neurological disorders such as epilepsy and neuropathic pain.
0 Comments
Leave a Reply. |